Overview
Agamree is approved by the U.S. Food and Drug Administration (FDA) for treating Duchenne muscular dystrophy (DMD) in people ages 2 years and older. It is prescribed for managing symptoms associated with DMD, a…

Overview
Amondys 45 is approved by the U.S. Food and Drug Administration (FDA) for treating Duchenne muscular dystrophy (DMD) in people with a confirmed mutation (variation) in the DMD gene that is responsive to exon 45…

Overview
Duvyzat is approved by the U.S. Food and Drug Administration (FDA) for treating Duchenne muscular dystrophy (DMD) in people who are 6 years of age and older. A person must undergo evaluations of their platelet…

Overview

Elevidys is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD) in children aged 4 years and older who are ambulatory (still able to walk) and have a…

Overview
Emflaza is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD) in people 2 years of age and older. It is specifically indicated for use in children and…

Overview
Exondys 51 is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD) in people with a confirmed mutation (variation) of the DMD gene that allows for exon 51…

Overview
Jaythari is a corticosteroid medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD) in people 5 years of age and older. To be eligible for…

Overview
Pyquvi is a corticosteroid medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD) in people 5 years of age and older. Pyquvi is also known by its…

Overview
Viltepso is approved by the U.S. Food and Drug Administration (FDA) under accelerated approval for treating Duchenne muscular dystrophy (DMD) in people with a specific mutation (variation) in the DMD gene that is…

Overview
Vyondys 53, approved by the U.S. Food and Drug Administration (FDA), is used to treat Duchenne muscular dystrophy (DMD) in people with a confirmed mutation (variation) of the DMD gene that allows for exon 53…